Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 4/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.37 |
| ▸ | KDR | P35968 | 4/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29933384 | 0.89 | KIT (0.49) | KITDDR1RIPK2CSF1RCNR1 | |
| SCHEMBL29933030 | 0.88 | TAS1R3 (0.48) | KITDDR1CSF1RCNR1ABL1 | |
| SCHEMBL29932947 | 0.87 | CNR1 (0.41) | CNR1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL31462416 | 0.86 | CNR1 (0.40) | CNR1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29933176 | 0.85 | KIT (0.47) | KITDDR1CSF1RCNR1ABL1 | |
| SCHEMBL29933322 | 0.84 | KIT (0.51) | KITDDR1CSF1RCNR1ABL1 | |
| SCHEMBL29933073 | 0.82 | KIT (0.47) | KITDDR1CSF1RCNR1 | |
| SCHEMBL29933061 | 0.82 | KIT (0.42) | KITDDR1RIPK2CSF1RCNR1 | |
| SCHEMBL29933145 | 0.82 | KIT (0.48) | KITDDR1CSF1RCNR1ABL1 | |
| SCHEMBL29933159 | 0.80 | LCK (0.54) | KITDDR1CNR1ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | claimed |
| CN-119371371-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2025-01-28 | — | — | CN | claimed |
| CN-115315421-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2022-11-08 | — | — | CN | claimed |
| CN-119371371-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2025-01-28 | — | — | CN | disclosed |
| CN-115315421-B | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2024-12-03 | — | — | CN | disclosed |
| CN-115315421-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2022-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | KIT 180/4885DDR1 1510/4885RIPK2 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.